MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
1.670
-0.020
-1.18%
After Hours: 1.670 0 0.00% 19:33 09/21 EDT
OPEN
1.690
PREV CLOSE
1.690
HIGH
1.740
LOW
1.630
VOLUME
482.55K
TURNOVER
--
52 WEEK HIGH
2.590
52 WEEK LOW
0.7006
MARKET CAP
75.37M
P/E (TTM)
-5.3219
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNXT last week (0907-0911)?
Weekly Report · 09/14 10:29
Weekly Report: what happened at RNXT last week (0831-0904)?
Weekly Report · 09/07 10:22
These low-priced stocks are flashing overbought signals
Seeking Alpha · 09/04 16:19
The best Quant-rated stocks trading below $10 right now
Seeking Alpha · 09/04 10:51
6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More
NASDAQ · 09/03 03:20
Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE
NASDAQ · 09/01 07:46
Weekly Report: what happened at RNXT last week (0824-0828)?
Weekly Report · 08/31 10:30
Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI
NASDAQ · 08/31 09:01
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.